BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld Science 2025 review
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Blogs » BioWorld Perspectives » Kudos to Four Little Biotechs Doing Cool Science

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Kudos to Four Little Biotechs Doing Cool Science

Sep. 26, 2011
By Trista Morrison

I recognize that while a lot of you busy biotech folk subscribe to BioWorld Today, I am probably one of the only people who actually reads every single word of the paper every single day.

In doing so, I often come across really cool companies doing really cool stuff that you might have missed if you were just scanning the headlines for news related to one particular indication or another. So here’s a shout-out to a few of the coolest little companies I’ve stumbled on recently:

ŸKingdoms Cross Station: NovaDigm Therapeutics Inc. just popped on the radar at ICAAC with the first vaccine shown to provide protection against pathogens from two kingdoms: fungi and bacteria. The NDV-3 vaccine is in Phase I development to prevent diseases caused by Candida and Staphylococcus aureus.

ŸProgrammable Immunity: Altermune Technologies LLC just raised $7 million in seed funding to support its work on programmable immunity. Founded by Nobel laureate and polymerase chain reaction inventor Kary Mullis, the firm is pursuing the theory that the immune system's own antibodies – ubiquitous antibodies that typically are not charged with fighting infection – can be recruited and directed against a desired pathogen.

ŸCancer Prevention: As its name indicates, Cancer Prevention Pharmaceuticals Inc. is trying to stop benign tumors from becoming malignant. Jumping off of work done in academia and at other firms, CPP is already poised for pivotal trials.

ŸWhere No Mab’s Gone Before: Permeon Biologics Inc. is using a class of natural proteins, dubbed intraphilins, to deliver biological molecules inside of cells. The approach could open up thousands of targets previously inaccessible to biologics.

Know of a biotech doing something super-cool? Tell us about it at newsdesk@bioworld.com

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Rubber duck dressed up as a doctor

    In 2025, science’s biggest story was political

    BioWorld
    In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
  • Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

    BioWorld Science
    Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing